CDMO 001
Alternative Names: CDMO-001Latest Information Update: 18 Jul 2023
At a glance
- Originator JECHO Biopharmaceuticals
- Class Antineoplastics; Bacteria; Immunotherapies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Solid tumours
Most Recent Events
- 18 Jul 2023 Phase-I clinical trials in Solid tumours in China (unspecified route) before July 2023 (JECHO Biopharmaceuticals pipeline, July 2023)